Clinical trials: Neoadjuvant Immunotherapy
Esophageal Cancer, Chemotherapy Effect
Neoadjuvant Treatment Modalities in Esophageal Cancer
Esophageal cancer is the most prevalent cancer globally with poor survival outcome. The prognosis with surgery alone is poor, accounting for 30-40% of overall survival at 5 year.
- Conditions
- Esophageal Cancer, Chemotherapy Effect, Chemoradiation, Surgery
- Trial name
- NCT04821843
- Testing
- Platinum based chemotherapy, Paclitaxel based chemotherapy, Radiotherpay
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Immunotherapy Gastroesophageal Junction
The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction
To evaluate the efficacy and safety of tislelizumab combined with antilotinib and SOX regimen for neoadjuvant treatment of locally advanced esophagogastric junction cancer
- Trial name
- NCT06396585
- Testing
- Tislelizumab, Anlotinib, Oxaliplatin
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Fujian Cancer Hospital
NSCLC (Non-small Cell Lung Cancer), MRD
Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
This is a multicenter, prospective, open-label Phase II study designed to evaluate the safety and efficacy of adjuvant sintilimab therapy guided by minimal residual disease (MRD) in patients with Stage II-IIIB non-small cell lung…
- Conditions
- NSCLC (Non-small Cell Lung Cancer), MRD, II-IIIB Stages, Adjuvant Immunotherapy
- Trial name
- CTONG 2508 (NCT07120698)
- Testing
- Sintilimab
- Where
- 2 sites in China
- Volunteers
- 115 people
- Sponsor
- Guangdong Association of Clinical Trials
DMMR Colorectal Cancer, Colon Cancer Stage I
Neoadjuvant Immunotherapy and Organ-sparing Treatment in Patients With Stage I-III dMMR Colon Cancer
The RESET C2 trial aims to introduce organ sparing treatment or watch-and-wait (WW) to patients with localized deficient mismatch repair (dMMR) colon cancer through use of neoadjuvant pembrolizumab.
- Conditions
- DMMR Colorectal Cancer, Colon Cancer Stage I, Colon Cancer Stage II/III, Pembrolizumab
- Trial name
- RESET C2 (NCT07409844)
- Testing
- 1 Cycle of Pembrolizumab, 2 Cycles of Pembrolizumab, 3 Cycles of Pembrolizumab
- Where
- Denmark
- Volunteers
- 152 people
- Sponsor
- Ismail Gögenur
Lung Cancer
Exploration of Predictive Markers of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer
Neoadjuvant immunotherapy has become the standard perioperative treatment in lung cancer, but its effective predictive biomarkers are lacking.
- Trial name
- NCT05965557
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Geneplus-Beijing Co. Ltd.
Melanoma, Melanoma Stage III
CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma
Combination treatment with nivolumab and ipilimumab before surgery may help people with melanoma because the drugs are designed to help the immune system target and destroy cancer cells (immunotherapy), which may shrink the…
- Trial name
- NCT05289193
- Testing
- PET Scan, Nivolumab, Ipilimumab
- Where
- 4 sites in United States
- Volunteers
- 28 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cervical Cancers
Iparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for CC
Currently, the survival rate of locally advanced cervical cancer is low, posing a significant challenge in the treatment of cervical cancer.
- Trial name
- NCT06878222
- Testing
- Neoadjuvant Chemotherapy, Immunotherapy, Radical surgery
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Obstetrics & Gynecology Hospital of Fudan University
Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
Background: Lung cancer is the leading cause of cancer-related death worldwide. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer.
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT06694454
- Testing
- azacytidine, carboplatin, paclitaxel
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Urothelial Carcinoma of the Renal Pelvis and Ureter, Neoadjuvant Therapy
Neoadjuvant Disitamab Vedotin, Toripalimab, and Radiotherapy for High-risk UTUC ( LUXUS07.1 )
This is an open-label, single-arm, single-cohort, prospective clinical study evaluating neoadjuvant antibody-drug conjugate therapy combined with immunotherapy and sequential radiotherapy followed by radical surgery in patients…
- Trial name
- LUXUS0701 (NCT07720921)
- Testing
- Neoadjuvant radiotherapy, ADC + PD1 monoclonal antibody
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University First Hospital
Triple Negative Breast Cancer, Breast Cancer
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
This study will assess if the presence of immune system cells in and around the tumor impacts tumor shrinkage in patients receiving neoadjuvant chemoimmunotherapy for triple-negative breast cancer.
- Trial name
- NeoTRACT (NCT05645380)
- Testing
- Carboplatin, Docetaxel, Doxorubicin
- Where
- 7 sites in United States
- Volunteers
- 139 people
- Sponsor
- University of Kansas Medical Center
Gastric Cancer
Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
This project aims to evaluate the efficacy and safety of oral taurine supplementation combined with PD-1 inhibitor (serplulimab) and chemotherapy in inducing systemic CD8+ T cell responses and achieving improved gastric cancer…
- Trial name
- NCT06128252
- Testing
- Taurine, Serplulimab, XELOX regimen
- Where
- 15 sites in China
- Volunteers
- 96 people
- Sponsor
- Tang-Du Hospital
Locally Advanced Rectal Cancer (LARC)
Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer.
This prospective, multi-center, phase II randomized controlled trial will evaluate the actual benefit of adding immunotherapy with tislelizumab to the currently most effective approach against LARC, namely TNT.
- Trial name
- TOTAL (NCT06940388)
- Testing
- Tislelizumab, Total neoadjuvant therapy (TNT)
- Where
- 2 sites in Germany, Israel
- Volunteers
- 134 people
- Sponsor
- brenner baruch
Nasopharyngeal Carcinoma
Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients
This is a randomized Phase II trial to study the effectiveness and toxicity of neoadjuvant and adjuvant PD-1 antibody Toripalimab combined with concurrent cisplatin chemoradiotherapy versus cisplatin concurrent chemoradiotherapy…
- Trial name
- NCT03925090
- Testing
- Cisplatin+Toripalimab
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Sun Yat-sen University
Adenocarcinoma of the Pancreas, Pancreas Cancer
Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B
Standard treatment for newly diagnosed operable pancreatic cancer usually involves undergoing surgery first and then receiving chemotherapy with or without radiation therapy.
- Trial name
- NCT03778879
- Testing
- CCX872-B
- Where
- United States
- Sponsor
- Alan Katz
Locally Advanced Cervical Cancer
Neoadjuvant Chemo-immunotherapy Followed by Concurrent Chemoradiotherapy and Immunotherapy in LACC
Concurrent chemoradiotherapy -immunotherapy followed by ICI maintenance was proved to improve the PFS by the Keynote-A18 in the LACC patients, and still more than 30% progressed.
- Trial name
- NCT06916117
- Testing
- Neoadjuvant Chemotherapy (NACT)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- RenJi Hospital
Sarcoma
Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma
Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma
- Trial name
- NCT03463408
- Testing
- nivolumab, ipilimumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Rochester
The Neoadjuvant Treatment for Resectable Esophageal Squamous Cell Carcinoma
a Neo-adjuvant Chemotherapy Immunotherapy in Resectable ESCC Study
Research Purpose 1: To evaluate the therapeutic efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in the treatment of resectable locally advanced esophageal squamous cell carcinoma (ESCC) in the…
- Trial name
- ANACIIRE-1 (NCT06472635)
- Where
- China
- Volunteers
- 95 people
- Sponsor
- Zhejiang University
Locally Advanced Colon Cancer, pMMR
Chemotherapy Combined With or Without Short-Course Radiotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for High-Risk Locally Advanced Colon Cancer With pMMR/MSS
Locally advanced colon cancer, particularly T4 disease or colon cancer with bulky nodes, carries a poor prognosis and limited efficacy with neoadjuvant chemotherapy.
- Trial name
- TORCH-C2 (NCT07877597)
- Testing
- short-course radiotherapy, Serplulimab, CapOx(Capecitabine+ Oxaliplatin)
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Fudan University
Non-Small Cell Lung Cancer, Adjuvant Therapy
Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC
This multicenter, randomized, open-label, phase II trial is designed to evaluate the efficacy and safety of adjuvant sintilimab in patients with completely resected non-small cell lung cancer who remain at high risk of recurrence…
- Conditions
- Non-Small Cell Lung Cancer, Adjuvant Therapy, Immune Checkpoint Inhibitors
- Trial name
- RICA (NCT07748325)
- Testing
- Sintilimab
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Sichuan University
Stage IIA-IIIB NSCLC, Selective Mediastinal Lymph Node Sampling
Selective Mediastinal Lymph Node Sampling Versus Systematic medIastinal Lymph Node Dissection After Neoadjuvant Chemoimmunotherapy for Non-small Cell Lung Cancer (SCIENCE Study)
The SCIENCE trial is a multicenter, open-label, randomized, parallel, noninferiority investigator-initiated trial (IIT). This study aims to evaluate the prognostic differences between selective mediastinal lymph node sampling and…
- Conditions
- Stage IIA-IIIB NSCLC, Selective Mediastinal Lymph Node Sampling, Systematic medIastinal Lymph Node Dissection
- Trial name
- NCT07617389
- Testing
- selective mediastinal lymph node sampling, systematic mediastinal lymph node dissection
- Where
- China
- Volunteers
- 358 people
- Sponsor
- Wen-zhao ZHONG